$TSEM

Fri: Weak defense stocks weigh on indices

Friday on the Tel Aviv Stock Exchange, major indices declined. Tel Aviv 35 fell 0.33% to 4,202.63 and Tel Aviv 125 fell 0.31% to 4,074.63. Defense and renewable energy sector indices dropped, while chemicals rubber and plastics rose. FX rates weakened versus the dollar and euro. Bank Hapoalim rose 0.31%, Tower Semiconductor fell 4.35%, Teva fell 2.28%.

Original reporting
Published Aug 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 16, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fri: Weak defense stocks weigh on indices — source image
Decision brief

The 30-second read

$TSEMNeutralLow
01

Why it matters

The only explicit fundamental event is Nofar Energy’s announced acquisition of HighLight for NIS 200 million; other listed moves are presented without catalysts.

02

Market read

Traders get a same-day read on TASE risk appetite, with defense and renewables under pressure and one deal-driven single-name catalyst.

03

What to watch

Defense and renewable weakness may reflect macro or hedging flows rather than company fundamentals; without attribution, single-name moves may be non-informational.

Relevance 4/10Novelty 3/10Timing: Friday session market wrap, mid-day timestamp (13:30 UTC)

Background

This is a Tel Aviv market wrap describing index performance, sector moves, FX moves, and a list of notable single-stock gainers and losers.

Company-level read

Ticker impact

$TSEMNeutralLow confidence
Context

Tower Semiconductor dropped 4.35% on Friday, listed as a notable decliner in the article.

Expected impact

Short-term volatility possible, but directionally unconfirmed by fundamentals here.

Evidence & confidence

The article lacks a catalyst; it is a market wrap with price moves only.

$TEVANeutralLow confidence
Context

Teva fell 2.28% on Friday, included in the article’s notable decliners list.

Expected impact

No high-conviction trade signal from this article alone.

Evidence & confidence

Only the daily move is provided; no earnings, trial, or guidance update appears.

$NICENeutralLow confidence
Context

Nice rose 6.48% on Friday, called out as a notable advancer in the article.

Expected impact

Potential momentum, but catalyst risk remains high without further detail.

Evidence & confidence

The article reports the move magnitude without explaining what drove it.

$GILTNeutralLow confidence
Context

Gilat Satellite Systems fell 4.43% on Friday, listed among notable decliners.

Expected impact

Limited actionable signal without a stated catalyst.

Evidence & confidence

No event, filing, or guidance change is described for Gilat.

Market effects

Defense and renewable energy sector indices fell 1.62% and 1.49%, suggesting risk-off rotation within TASE sectors.

Broader Tel Aviv index weakness alongside shekel depreciation (USD -0.97%, EUR -0.83%) may pressure risk assets.

Limited direct global linkage; mainly a regional tape and sector rotation snapshot.

Counterpoint

The article’s biggest single-company catalyst is an acquisition, but the stock drop could be an overreaction that reverses if deal terms are later clarified.

Key entities

  • Tel Aviv 35 Index

    Fell 0.33% to 4,202.63 points on Friday.

  • Tel Aviv Defense Index

    Dropped 1.62% on Friday.

  • Nofar Energy

    Fell 5.42% after announcing acquisition of HighLight for NIS 200 million.

  • HighLight

    Solar energy and storage company being acquired by Nofar Energy.

Related articles

$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

$TEVAHighAI 9/10

FDA nod for Teva’s Degevma biosimilar

Teva Pharmaceutical Industries (TEVA) received FDA approval for Degevma, a biosimilar to Amgen's Xgeva (denosumab). Degevma is indicated for preventing bone complications in advanced cancer, treating giant cell tumors, and managing hypercalcemia of malignancy. This approval expands Teva's oncology portfolio.